|
|
|
|
|||||
|
|
|
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Best Up and Coming Canadian Stocks to Buy. AbCellera Biologics Inc. (NASDAQ:ABCL) is down more than 23% since its fiscal Q3 2025 business update on November 6. However, Wall Street maintains a bullish sentiment with analysts’ 12-month average price target of $8.5, reflecting 144.96% upside from the current level.
On November 19, David Martin, PhD, from Bloom Burton reiterated a Buy rating on the stock with a price target of $9. Earlier on November 10, Srikripa Devarakonda from Truist Financial also reiterated a Buy rating on the stock without disclosing any price targets.
AbCellera Biologics Inc. (NASDAQ:ABCL) grew its revenue by 37.62% year-over-year to $8.96 million, surpassing estimates by $2.62 million. However, the EPS of negative $0.19 fell short of the expectations by $0.03. Management noted that their ABCL635 and ABCL575 continue to progress through Phase 1 clinical trials, and the company reached 103 partner-initiated program starts with downstreams.
Later on November 13, AbCellera Biologics Inc. (NASDAQ:ABCL) also presented at the Stifel 2025 Healthcare Conference, where management highlighted its strategic shift from partnerships to developing its own clinical assets. The company still values its partnerships with big pharma, including Lilly and AbVie. However, it is leveraging its capabilities and technologies to build its own clinical assets.
AbCellera Biologics Inc. (NASDAQ:ABCL) discovers and develops antibody-based medicines targeting cancer, metabolic/endocrine conditions, and autoimmune disorders. The company uses an AI-powered platform that integrates technology, data science, and microfluidics for rapid single-cell screening.
While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
| Dec-04 | |
| Nov-25 | |
| Nov-18 | |
| Nov-07 | |
| Nov-06 | |
| Nov-06 | |
| Oct-21 | |
| Oct-07 | |
| Sep-30 | |
| Sep-29 | |
| Sep-29 | |
| Sep-21 | |
| Sep-20 | |
| Sep-15 | |
| Sep-10 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite